Clinical Trials Browser

Phase 2/3 × Colorectal Neoplasms × 90 days × Clear all

NCT06280495 2026-04-20

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07509398 2026-04-03

FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02758951 2026-03-24

CAIRO6

Phase 2/3 Active not recruiting

GastrointestinalGynecologic

Hyperthermia, Colonic Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT00208260 2026-02-05

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Phase 2/3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms